FDA Output
FDA Output, March 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in March 2026. Updated March 20.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Start-Ups
MedTech Capital Matters March 2026
The best private financing deals in February across all clinical categories, and a profile of Israel’s Edge Medical Ventures, which offers portfolio companies a novel commercialization strategy.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Regulatory & Reimbursement
FDA Digital Device Rise
Digital device approvals are way up from last year. Excerpted from Pathways' Picks March 11: CDRH Hiring Push, UK Taps Former FDAer, Global Policy Updates.